News coverage about Bruker (NASDAQ:BRKR) has trended somewhat positive recently, according to Accern. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Bruker earned a news sentiment score of 0.22 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 46.8264092420642 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Several equities research analysts recently commented on BRKR shares. BidaskClub cut Bruker from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Goldman Sachs Group reissued a “sell” rating and set a $24.00 target price on shares of Bruker in a research note on Tuesday, September 26th. J P Morgan Chase & Co raised Bruker from an “underweight” rating to a “neutral” rating and set a $28.00 target price for the company in a research note on Friday, November 3rd. Bank of America raised Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 target price for the company in a research note on Friday, November 3rd. Finally, Cowen reissued a “hold” rating and set a $29.00 target price on shares of Bruker in a research note on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have given a buy rating to the stock. Bruker has an average rating of “Hold” and an average target price of $29.64.

Bruker (NASDAQ:BRKR) traded down $0.17 during mid-day trading on Wednesday, reaching $33.56. The company’s stock had a trading volume of 384,632 shares, compared to its average volume of 629,917. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.60 and a current ratio of 2.60. The firm has a market capitalization of $5,220.00, a PE ratio of 28.76, a price-to-earnings-growth ratio of 2.84 and a beta of 1.11. Bruker has a one year low of $21.03 and a one year high of $36.53.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.02. Bruker had a return on equity of 25.83% and a net margin of 8.85%. The company had revenue of $435.60 million during the quarter, compared to analysts’ expectations of $415.45 million. During the same quarter last year, the firm earned $0.32 earnings per share. The firm’s quarterly revenue was up 10.6% compared to the same quarter last year. analysts predict that Bruker will post 1.19 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 22nd. Stockholders of record on Monday, December 4th will be given a dividend of $0.04 per share. The ex-dividend date is Friday, December 1st. This represents a $0.16 annualized dividend and a dividend yield of 0.48%. Bruker’s dividend payout ratio is currently 17.02%.

In other news, VP Mark Munch sold 21,061 shares of the firm’s stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $29.97, for a total transaction of $631,198.17. Following the completion of the transaction, the vice president now directly owns 60,524 shares in the company, valued at $1,813,904.28. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 35.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at

About Bruker

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Insider Buying and Selling by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.